Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction

被引:15
作者
Tanaka, Hiroaki [1 ]
Kubo, Michiko [1 ]
Nii, Masafumi [1 ]
Maki, Sintarou [1 ]
Umekawa, Takashi [1 ]
Ikeda, Tomoaki [1 ]
机构
[1] Mie Univ, Sch Med, Dept Obstet & Gynecol, 2-174 Edobashi, Tsu, Mie, Japan
关键词
fetal growth restriction; pre-eclampsia; tadalafil; SILDENAFIL CITRATE VIAGRA; MANAGEMENT;
D O I
10.1111/jog.13335
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
For severe pre-eclampsia (PE) with fetal growth restriction (FGR), the only effective treatment is early delivery of the placenta. Clinicians are often forced to end the pregnancy because of maternal indications. We report a case of severe PE with FGR in which the PE was temporarily improved and pregnancy successfully prolonged with tadalafil, a phosphodiesterase 5 inhibitor. A 35-year-old primigravid woman presented at 27 3/7 weeks of gestation with severe PE and FGR. After commencing tadalafil administration, biochemical and angiogenic markers improved. Thereafter, hypertension and proteinuria temporarily improved. Importantly, the pregnancy was prolonged by 14 days after the initiation of tadalafil administration. Tadalafil may be a novel treatment for severe PE with FGR to prolong pregnancy.
引用
收藏
页码:1205 / 1208
页数:4
相关论文
共 15 条
[1]  
ACOG, 2002, OBSTET GYNECOL, V99, P869
[2]   Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia [J].
Amorim, MMR ;
Santos, LC ;
Faúndes, A .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (05) :1283-1288
[3]   Expectant Management in Pregnancies with Severe Pre-eclampsia [J].
Haddad, Bassam ;
Sibai, Baha M. .
SEMINARS IN PERINATOLOGY, 2009, 33 (03) :143-151
[4]   Sildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats [J].
Herraiz, S. ;
Pellicer, B. ;
Serra, V. ;
Cauli, O. ;
Cortijo, J. ;
Felipo, V. ;
Pellicer, A. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2012, 119 (11) :1394-1402
[5]   Relaxant action of sildenafil citrate (Viagra) on human myometrium of pregnancy [J].
Khan, RN ;
Hamoud, H ;
Warren, A ;
Wong, LF ;
Arulkumaran, S .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (01) :315-321
[6]   Circulating angiogenic factors and the risk of preeclampsia [J].
Levine, RJ ;
Maynard, SE ;
Qian, C ;
Lim, KH ;
England, LJ ;
Yu, KF ;
Schisterman, EF ;
Thadhani, R ;
Sachs, BP ;
Epstein, FH ;
Sibai, BM ;
Sukhatme, VP ;
Karumanchi, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (07) :672-683
[7]   The impact of fetal growth restriction on latency in the setting of expectant management of preeclampsia [J].
McKinney, David ;
Boyd, Heather ;
Langager, Amanda ;
Oswald, Michael ;
Pfister, Abbey ;
Warshak, Carri R. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (03) :395.e1-395.e7
[8]   Sildenafil citrate decreases sFlt-1 and sEng in pregnant L-NAME treated Sprague-Dawley rats [J].
Ramesar, S. V. ;
Mackraj, I. ;
Gathiram, P. ;
Moodley, J. .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2011, 157 (02) :136-140
[9]   A Randomised, Double-Blinded, Placebo-Controlled Study of the Phosphodiesterase Type 5 Inhibitor Sildenafil for the Treatment of Preeclampsia [J].
Samangaya, Rebekah A. ;
Mires, Gary ;
Shennan, Andrew ;
Skillern, Laurence ;
Howe, David ;
McLeod, Alison ;
Baker, Philip N. .
HYPERTENSION IN PREGNANCY, 2009, 28 (04) :369-382
[10]  
SCHIFF E, 1994, OBSTET GYNECOL, V84, P626